ArticleClinical case reports2025
Rare Extraoral Plasmablastic Lymphoma in the Context of HIV and Toxoplasmosis: A Detailed Case Analysis With Therapeutic Insights.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rare Extraoral Plasmablastic Lymphoma in the Context of HIV and Toxoplasmosis: A Detailed Case Analysis With Therapeutic Insights.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL), a rare aggressive B-cell malignancy linked to HIV, is increasingly noted in extraoral sites beyond its traditional oral cavity presentation. This case report details a 48-year-old HIV-positive woman with prior cerebral toxoplasmosis, presenting with facial swelling, pain, proptosis, and dysphagia despite antiretroviral therapy and cotrimoxazole prophylaxis (CD4 120 cells/μL, suboptimal viral suppression). Imaging identified a sinonasal mass with nasopharyngeal involvement and lymphadenopathy, with immunohistochemistry confirming PBL (MUM1+, weakly CD79a+, CD20-, CD138-, EBER-). Treatment comprised six cycles of dose-adjusted EPOCH with bortezomib (1.3 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.